Andrew Shim

Andrew Shim

Company: Turning Point Therapeutics

Job title: Executive Director, Head, Global HEOR & RWE, Medical Affairs, Oncology


Using Expanded Access Programs (EAPs) to Generate Meaningful Clinical and Real-World Evidence in Rare, Biomarker Driven NSCLC 11:30 am

Conventional clinical trials in rare, biomarker driven NSCLC patient populations are becoming increasingly challenging and competitive Utilizing Expanded Access Programs to generate additional clinical and real-world evidence is becoming increasingly important Balancing data collection with site personnel and patient burden for EAPs is key to achieving successRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.